Related Experiment Video
Updated: May 31, 2026
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Obesity paradox and chronic kidney disease
I Valocikova1, G Valocik, B Kristofova
11st Department of Internal Medicine, University Hospital L. Pasteur, Kosice, Slovakia. irosochova@hotmail.com
Bratislavske Lekarske Listy
|July 13, 2011
Summary
Obesity may not harm kidney and heart function in chronic kidney disease patients. Obese individuals with CKD showed better renal function and cardiac output compared to normal-weight patients.
Area of Science:
- Nephrology
- Cardiology
- Obesity Medicine
Background:
- Obesity is generally linked to adverse health outcomes.
- However, in chronic disease states like heart and kidney disease, obesity may paradoxically improve patient outcomes.
Purpose of the Study:
- To investigate the influence of Body Mass Index (BMI) on renal and cardiac functions in patients with chronic kidney disease (CKD).
Main Methods:
- A retrospective study was conducted on 93 patients (51 males, 42 females; mean age 60.83 years) diagnosed with CKD.
- Patients were categorized based on K/DOQI guidelines for chronic renal failure stages.
Main Results:
- Obese patients (BMI >30) exhibited significantly higher Glomerular Filtration Rate (GFR) and lower creatinine levels compared to normal-weight individuals (p=0.0009 and p=0.05).
- Obese patients also showed significantly higher Ejection Fraction (EF) (p=0.05) and systolic myocardial velocity (S vel) (p=0.04).
- No significant differences were observed in B-type natriuretic peptide, C-reactive protein, or fibrinogen levels across groups.
Conclusions:
- In this cohort of 93 CKD patients, obesity did not demonstrate an adverse effect on cardiac or renal function.
- The findings suggest a potential protective role of obesity in the context of chronic kidney disease.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...